Dysregulation of tetrahydrobiopterin metabolism in myalgic encephalomyelitis/chronic fatigue syndrome by pentose phosphate pathway.
Bulbule, Sarojini, Gottschalk, Carl Gunnar, Drosen, Molly E et al. · Journal of central nervous system disease · 2024 · DOI
Quick Summary
Researchers found that patients with ME/CFS who experience dizziness upon standing have abnormally high levels of certain molecules called biopterins in their blood. The study discovered that these molecules are produced through an unusual metabolic pathway involving the breakdown of glucose, and this pathway appears to trigger inflammation in immune cells. This finding suggests a potential biochemical explanation for some ME/CFS symptoms.
Why It Matters
This study identifies a specific molecular mechanism that could explain both the orthostatic intolerance and inflammatory symptoms seen in some ME/CFS patients. Understanding this metabolic dysregulation opens potential avenues for biomarkers to identify ME+OI subgroups and for targeted therapeutic interventions. The findings bridge cellular metabolism, immune activation, and clinical symptoms in a way that could advance personalized medicine approaches.
Observed Findings
BH4 and BH2 levels are strongly elevated in plasma of ME/CFS patients with orthostatic intolerance compared to controls.
Non-oxidative pentose phosphate pathway enzymes (G6PDH, TALDO1, transketolase) show increased expression and activity in ME+OI-associated biological samples.
In hypoxic human microglial cell culture, activation of the pentose phosphate pathway increases BH4 and BH2 production via the purine biosynthetic route.
Knockdown of the TALDO1 gene reduced PRPP availability, suppressed purine biosynthetic enzymes, decreased GTPCH1 expression, and blocked BH4/BH2 production.
Plasma from ME+OI patients containing elevated BH4 increased iNOS expression and nitric oxide production in human microglial cells, suggesting pro-inflammatory activity.
Inferred Conclusions
Activation of the non-oxidative pentose phosphate pathway is a critical regulator of biopterin overproduction in ME/CFS patients with orthostatic intolerance.
Biopterins generated through this pathway may drive or amplify neuroinflammatory responses in ME/CFS, potentially contributing to symptom severity.
The purine biosynthetic pathway and GTPCH1 enzyme activity are key intermediate steps linking PPP activation to biopterin biogenesis in ME+OI.
Remaining Questions
Is the elevated pentose phosphate pathway activity a cause or consequence of ME+OI, and what triggers this dysregulation in the first place?
What This Study Does Not Prove
This study does not establish whether elevated biopterins cause orthostatic intolerance or are merely associated with it; the direction of causality remains unclear. The in vitro cell culture findings, while suggestive, do not directly prove this pathway operates identically in living ME/CFS patients. The study also does not demonstrate that targeting this pathway would be therapeutically effective or safe.
Do elevated biopterins directly cause orthostatic intolerance symptoms, or are they a marker of a broader metabolic or immune disturbance?
Could pharmacological inhibition of PPP or TALDO1 reduce biopterin levels and alleviate symptoms in ME/CFS patients, and would this be safe and tolerable?
How does hypoxia in vivo relate to the hypoxic cell culture conditions, and do ME/CFS patients actually experience tissue hypoxia that drives this pathway?